Evaluation of Expression and Clinicopathological Relevance of
Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer

J 2025

Evaluation of Expression and Clinicopathological Relevance of Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer

ZÁVESKÝ, Luděk; Eva JANDÁKOVÁ; Vít WEINBERGER; Luboš MINÁŘ; Radovan TURYNA et al.

Základní údaje

Originální název

Evaluation of Expression and Clinicopathological Relevance of Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer

Autoři

ZÁVESKÝ, Luděk; Eva JANDÁKOVÁ; Vít WEINBERGER; Luboš MINÁŘ; Radovan TURYNA; Adéla TEFR FARIDOVÁ; Veronika HANZÍKOVÁ a Ondřej SLANAŘ

Vydání

Non-Coding RNA, Basel, MDPI, 2025, 2311-553X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.000 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00142484

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

biomarker; breast cancer; small nucleolar RNA; SCARNA2; SCARNA3; SNORD15B; SNORD94; SNORA68; SNHG1; RNU2-1

Štítky

14110230, 14110240, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 2. 2026 13:25, Mgr. Tereza Miškechová

Anotace

V originále

Background/Objectives: Breast cancer is a leading cause of cancer-related mortality among women worldwide. Small nucleolar RNAs (snoRNAs) represent a class of non-coding RNAs with potential as novel biomarkers applicable to improve diagnostic and prognostic applications. Methods: We performed a comprehensive evaluation of the snoRNA-related gene expression by qPCR using benign and tumor tissue samples associated with invasive breast carcinomas of no special type (NST). Selected candidate snoRNAs, i.e., SCARNA2, SCARNA3, SNORD15B, SNORD94, SNORA68, and SNHG1, along with RNU2-1 snRNA, were further validated and their associations with clinicopathological parameters were examined. External datasets and plasma samples were used for additional validation. Results: SCARNA2 was identified as the most promising snoRNA biomarker candidate, showing a positive association with better progression-free survival (PFS) in our data (13.3-month survival difference between low- and high-expression groups) and with both PFS and overall survival in external RNA-seq datasets. SNORD94, SNORD15B, SCARNA3, and RNU2-1 snRNA were also indicated as putative tumor suppressors. SNORD94 was associated with better progression-free survival (PFS) in our data as well (12.4-month survival difference between low- and high expression groups). Greater downregulation in the low-expression tumor subgroup compared to benign samples further supports the prognostic potential of SCARNA2 and SNORD94. Evidence for SNHG1 and SNORA68 as putative oncogenes was less conclusive. Conclusions: Several small nucleolar RNAs were found to be dysregulated in breast cancer specimens, supporting their further evaluation as potential biomarkers. In particular, SCARNA2, SNORD94, SNORD15B, SCARNA3, and RNU2-1 snRNA merit further investigation to determine their clinical relevance and biological roles in breast cancer.

Citovat

ZÁVESKÝ, Luděk; Eva JANDÁKOVÁ; Vít WEINBERGER; Luboš MINÁŘ; Radovan TURYNA; Adéla TEFR FARIDOVÁ; Veronika HANZÍKOVÁ a Ondřej SLANAŘ. Evaluation of Expression and Clinicopathological Relevance of Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer. Non-Coding RNA. Basel: MDPI, 2025, roč. 11, č. 6, s. 1-21. ISSN 2311-553X. Dostupné z: https://doi.org/10.3390/ncrna11060076.

@article{2531024,
   author = {Záveský, Luděk and Jandáková, Eva and Weinberger, Vít and Minář, Luboš and Turyna, Radovan and Tefr Faridová, Adéla and Hanzíková, Veronika and Slanař, Ondřej},
   article_location = {Basel},
   article_number = {6},
   doi = {https://doi.org/10.3390/ncrna11060076},
   keywords = {biomarker; breast cancer; small nucleolar RNA; SCARNA2; SCARNA3; SNORD15B; SNORD94; SNORA68; SNHG1; RNU2-1},
   language = {eng},
   issn = {2311-553X},
   journal = {Non-Coding RNA},
   title = {Evaluation of Expression and Clinicopathological Relevance of Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer},
   url = {https://www.mdpi.com/2311-553X/11/6/76},
   volume = {11},
   year = {2025}
}

TY  - JOUR
ID  - 2531024
AU  - Záveský, Luděk - Jandáková, Eva - Weinberger, Vít - Minář, Luboš - Turyna, Radovan - Tefr Faridová, Adéla - Hanzíková, Veronika - Slanař, Ondřej
PY  - 2025
TI  - Evaluation of Expression and Clinicopathological Relevance of Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer
JF  - Non-Coding RNA
VL  - 11
IS  - 6
SP  - 1-21
EP  - 1-21
PB  - MDPI
SN  - 2311553X
KW  - biomarker
KW  - breast cancer
KW  - small nucleolar RNA
KW  - SCARNA2
KW  - SCARNA3
KW  - SNORD15B
KW  - SNORD94
KW  - SNORA68
KW  - SNHG1
KW  - RNU2-1
UR  - https://www.mdpi.com/2311-553X/11/6/76
N2  - Background/Objectives: Breast cancer is a leading cause of cancer-related mortality among women worldwide. Small nucleolar RNAs (snoRNAs) represent a class of non-coding RNAs with potential as novel biomarkers applicable to improve diagnostic and prognostic applications. Methods: We performed a comprehensive evaluation of the snoRNA-related gene expression by qPCR using benign and tumor tissue samples associated with invasive breast carcinomas of no special type (NST). Selected candidate snoRNAs, i.e., SCARNA2, SCARNA3, SNORD15B, SNORD94, SNORA68, and SNHG1, along with RNU2-1 snRNA, were further validated and their associations with clinicopathological parameters were examined. External datasets and plasma samples were used for additional validation. Results: SCARNA2 was identified as the most promising snoRNA biomarker candidate, showing a positive association with better progression-free survival (PFS) in our data (13.3-month survival difference between low- and high-expression groups) and with both PFS and overall survival in external RNA-seq datasets. SNORD94, SNORD15B, SCARNA3, and RNU2-1 snRNA were also indicated as putative tumor suppressors. SNORD94 was associated with better progression-free survival (PFS) in our data as well (12.4-month survival difference between low- and high expression groups). Greater downregulation in the low-expression tumor subgroup compared to benign samples further supports the prognostic potential of SCARNA2 and SNORD94. Evidence for SNHG1 and SNORA68 as putative oncogenes was less conclusive. Conclusions: Several small nucleolar RNAs were found to be dysregulated in breast cancer specimens, supporting their further evaluation as potential biomarkers. In particular, SCARNA2, SNORD94, SNORD15B, SCARNA3, and RNU2-1 snRNA merit further investigation to determine their clinical relevance and biological roles in breast cancer.
ER  -

ZÁVESKÝ, Luděk; Eva JANDÁKOVÁ; Vít WEINBERGER; Luboš MINÁŘ; Radovan TURYNA; Adéla TEFR FARIDOVÁ; Veronika HANZÍKOVÁ a Ondřej SLANAŘ. Evaluation of Expression and Clinicopathological Relevance of Small Nucleolar RNAs (snoRNAs) in Invasive Breast Cancer. \textit{Non-Coding RNA}. Basel: MDPI, 2025, roč.~11, č.~6, s.~1-21. ISSN~2311-553X. Dostupné z: https://doi.org/10.3390/ncrna11060076.

Přehled o publikaci